-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Undisclosed 1 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Undisclosed 1 in Autoimmune Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Undisclosed 1 in Autoimmune Disorders Drug Details: The therapeutic candidate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erlotinib in Palmoplantar Keratoderma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erlotinib in Palmoplantar Keratoderma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erlotinib in Palmoplantar Keratoderma Drug Details: Erlotinib is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IPH-6101 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IPH-6101 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IPH-6101 in Refractory Acute Myeloid Leukemia Drug Details: IPH-6101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Primary Mediastinal B-Cell Lymphoma Drug Details: Durvalumab...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-3804 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-3804 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-3804 in Non-Small Cell Lung Cancer Drug Details: TQB-3804...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISN-001 in Muscle Injury
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ISN-001 in Muscle Injury Drug Details: ISN-001 (ALLO-ASC) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AXER-204 in Chronic Spinal Cord Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AXER-204 in Chronic Spinal Cord Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AXER-204 in Chronic Spinal Cord InjuryDrug Details:AXER-204 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Gouty Arthritis (Gout)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Gouty Arthritis (Gout) Drug Details: Dapansutrile (OLT-1177) is under development for the treatment...